News & Views
Milestone reached in Target Discovery Alliance
Jan 05 2023
Since entering a multi-project target discovery collaboration in January 2020, when PhoreMost deployed its phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways selected by Boehringer Ingelheim, PhoreMost has triggered a milestone payment, achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies to transform patients’ lives.
“The success of this project to date provides significant validation of our SITESEEKER platform and its capabilities in novel target discovery and is testament to the expertise and great collaborative efforts of the teams at both PhoreMost and Boehringer Ingelheim. We are proud to contribute to the development of much needed new therapies for patients by delivering on this first key milestone and look forward to continuing this very fruitful partnership” said Dr. Neil Torbett, Chief Executive Officer, PhoreMost.
The development of potential new therapies will now be continued at Boehringer Ingelheim leading to possible further success based pre-clinical, clinical and commercial milestone payments.
Further information online
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark